Circular RNAs: An emerging precise weapon for diabetic nephropathy diagnosis and therapy - 11/11/23
Abstract |
Diabetic nephropathy (DN) is a prevalent chronic microvascular complication associated with diabetes mellitus and represents a major cause of chronic kidney disease and renal failure. Current treatment strategies for DN primarily focus on symptom alleviation, lacking effective approaches to halt or reverse DN progression. Circular RNA (circRNA), characterized by a closed-loop structure, has emerged as a novel non-coding RNA regulator of gene expression, attributed to its conservation, stability, specificity, and multifunctionality. Dysregulation of circRNA expression is closely associated with DN progression, whereby circRNA impacts kidney cell injury by modulating cell cycle, differentiation, cell death, as well as influencing the release of inflammatory factors and stromal fibronectin expression. Consequently, circRNA is considered a predictive biomarker and a potential therapeutic target for DN. This review provides an overview of the latest research progress in the classification, functions, monitoring methods, and databases related to circRNA. The paper focuses on elucidating the impact and underlying mechanisms of circRNA on kidney cells under diabetic conditions, aiming to offer novel insights into the prevention, diagnosis, and treatment of DN.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | CircRNAs are involved in the progression of diabetic nephropathy. |
• | CircRNAs have potential as biomarkers for the diagnosis of diabetic nephropathy. |
• | CircRNAs are promising for treatment of diabetic nephropathy. |
Keywords : Diabetes nephropathy, Circular RNA, Biomarker, Therapeutic target, Database
Plan
Vol 168
Article 115818- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?